Skip to navigation bar Skip to breadcrumbs Skip to page content
Envelope icon E-mail Updates Teal square Text size:  a A A

Cervical Cancer: Screening

Release Date: March 2012

Recommendation Summary

Summary of Recommendations and Evidence

PopulationRecommendationGrade
(What's This?)
Women 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing)

The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. See the Clinical Considerations for discussion of cytology method, HPV testing, and screening interval.

The USPSTF recommends the service. There is high certainty that the net benefit is substantial.
Women younger than 30 years, HPV testing

The USPSTF recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years.

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits
Women younger than 21

The USPSTF recommends against screening for cervical cancer in women younger than age 21 years.

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits
Women Older than 65, who have had adequate prior screening

The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer. See the Clinical Considerations for discussion of adequacy of prior screening and risk factors.

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits
Women who have had a hysterectomy

The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not have a history of a high-grade precancerous lesion (cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer.

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits

This recommendation statement applies to women who have a cervix, regardless of sexual history. This recommendation statement does not apply to women who have received a diagnosis of a high-grade precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, or women who are immunocompromised (such as those who are HIV positive).

 
Current as of: September 2013

Internet Citation: Recommendation Summary. U.S. Preventive Services Task Force. September 2014.
http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/cervical-cancer-screening

USPSTF Program Office   540 Gaither Road, Rockville, MD 20850